Dinah Sah, PhD, is Chief Scientific Officer at Voyager Therapeutics, a young biotech company focused on the development of AAV gene therapies for the treatment of severe CNS disorders. She is an experienced executive with 24 years of biotechnology R&D experience in multiple therapeutic areas with a focus on neuroscience, and in the discovery and development of new classes of drugs such as RNA interference and AAV gene therapy. Her past roles include leadership positions at Alnylam Pharmaceuticals and Biogen. Dr. Sah has extensive leadership experience including serving as a member of senior management and R&D management teams, head of focus/therapeutic area committee, head of research department, and leader of multiple programs from early research through IND/Phase 1 clinical trials with cross-functional teams comprising research, pre-clinical safety/toxicology, DMPK, CMC, clinical, and regulatory. She has had a key role in the management of major corporate partnerships with pharmaceutical, medical device and biotech companies, development of long-term neuroscience research strategy, and scientific/technical assessment of numerous in-licensing/partnering opportunities. Dr. Sah has direct experience with building departments from their inception at start-up biotechnology companies. She is an inventor on more than 30 patents, and author of numerous publications that include 19 articles in the Nature series, Molecular Therapeutics, Neuron, PNAS, EMBO Journal, and New England Journal of Medicine, across diverse research areas.